MIRA Pharmaceuticals' Topical Ketamir-2 Matches Injected Morphine in Pain Study

MIRA Pharmaceuticals has announced preclinical data revealing that its topical Ketamir-2 cream offers pain relief comparably effective to injected morphine. The Florida-based company demonstrated Ketamir-2's efficacy in reducing acute and inflammatory pain in a formalin-induced animal model. This model, which triggers both immediate acute pain and a prolonged inflammatory response, highlighted Ketamir-2's ability to nearly eliminate pain behaviors during the acute phase and maintain effects throughout the inflammatory phase.

Ketamir-2, applied topically 30 minutes before the induction of pain, shows promise for localized pain treatment without the systemic side effects associated with traditional analgesics. The topical relief targets conditions like diabetic neuropathy and osteoarthritis, aligning with a projected $11.5 billion U.S. market for topical pain solutions by 2025. MIRA's dual-path approach with oral and topical formulations aims to deliver comprehensive pain management solutions.